Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: besifloxacin Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

NCT01193504
View directory record Official record
Conditions
Pseudophakia, Cataract Surgery
Interventions
Pred Forte, Lotemax
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 4 Interventional Results available

Study of Ocular Penetration of Topically Administered Fluoroquinolones

NCT00924729
View directory record Official record
Conditions
Cataract Extraction
Interventions
Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Nov 15, 2026, 7:23 AM EST
Terminated Phase 3 Interventional Results available

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

NCT01740388
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besifloxacin, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Year and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

NCT01431170
View directory record Official record
Conditions
Congenital Nasolacrimal Duct Obstruction
Interventions
Besivance Treatment Group, Polytrim Treatment Group
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
1 Month to 12 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

NCT00905762
View directory record Official record
Conditions
Healthy
Interventions
Gatifloxacin, Moxifloxacin, Besifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Nov 15, 2026, 7:23 AM EST
Terminated Phase 3 Interventional Results available

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

NCT01330355
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besivance, Gatifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Day to 31 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 1 Interventional

Systemic Pharmacokinetics of BOL-303224-A

NCT00407589
View directory record Official record
Conditions
Conjunctivitis, Bacterial
Interventions
BOL-303224-A
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

NCT01296542
View directory record Official record
Conditions
Cataracts
Interventions
Moxifloxacin Ophthalmic, Besifloxacin Ophthalmic
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

NCT01120418
View directory record Official record
Conditions
Healthy
Interventions
Besifloxacin Ophthalmic Suspension 0.6%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

NCT01296191
View directory record Official record
Conditions
Cataracts
Interventions
Moxifloxacin, besifloxacin
Drug
Lead sponsor
Frank A. Bucci, Jr., M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 4 Interventional

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233
View directory record Official record
Conditions
Corneal Health, Cataract Surgery
Interventions
besivance, vigamox
Drug
Lead sponsor
Ophthalmology Consultants, Ltd.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 2Phase 3 Interventional Results available

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

NCT00972777
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besifloxacin, Vehicle (Placebo)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Year and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Nov 15, 2026, 7:23 AM EST
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 4 Interventional Results available

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

NCT01478256
View directory record Official record
Conditions
Blepharitis
Interventions
Erythromycin, Besifloxocin
Drug
Lead sponsor
John, George, M.D.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 1 Interventional Results available

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

NCT00824070
View directory record Official record
Conditions
Cataract Extraction
Interventions
Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Nov 15, 2026, 7:23 AM EST
Completed Phase 3 Interventional Results available

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

NCT01175590
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besivance, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Year and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Nov 15, 2026, 7:23 AM EST